---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-24-000143"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:36:52.146160+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GRI Bio raises $13.9M in gross proceeds since Jan 2024; cash runway into mid Q1 2025

## Summary
- Closed Oct 22 warrant exercise for 762,236 shares raising $0.8M gross proceeds.
- Total gross proceeds since start of 2024 are approximately $13.9M.
- Cash runway estimated into mid Q1 2025, supporting Phase 2a interim data for GRI-0621 (IPF).
- Issued new Series D-1 and D-2 warrants with exercise price of $1.00 per share.
- H.C. Wainwright acted as exclusive placement agent for the offering.

## SEC filing metadata
- accession: 0001824293-24-000143
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000143/0001824293-24-000143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000143/val-20241024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-24-000143
- JSON: https://secwatch.observer/filing/0001824293-24-000143.json
- Plain text: https://secwatch.observer/filing/0001824293-24-000143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.